Susan Faas McKnight,Roxanne Cofiell,Anjli Kukreja,Krystin A. Bedard,Yan Yan
申请号：
US15287162
公开号：
US09658236B2
申请日:
2016.10.06
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.
